Here are seven key takeaways:
1. Analysts note that despite its relatively small size, Smith & Nephew has focused on meaningful innovation, thus becoming a significant contributor in the orthopedic device market.
2. Smith & Nephew pioneered its knee replacement device with Verilast technology, which, it claims, can last for 30 years.
3. This technology helps the company attract younger patients.
4. However, the company’s small size, and hence relatively small market share, could work against the company.
5. Hospitals will likely stick with larger vendors whose products many orthopedic surgeons already use.
6. Thus, according to analysts, Smith & Nephew could pair up with another company to better compete in the market.
7. There were rumors over the past year that Stryker was interested in Smith & Nephew, however, the deal is no longer imminent.
More articles on devices:
SeaSpine creates general counsel position: 5 things to know
IlluninOss Medical partners with Orthovactive
Amendia, Promimic enter into strategic venture: 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
